Tollys presents scientific data supporting preclinical proof of concept for TL-532, its cancer immunotherapy drug candidate
Doctors Marc Bonnin and Sylvain Thierry will present Tollys’ results at the European Association of Cancer Research’s EACR 2021 Congress, which will take place from June 9 -12
Confirmation by MATWIN’s panel of scientific and industry experts of therapeutic potential of TL-532 major boost for Tollys, supports moving flagship product towards clinical phase.
Drawing on her expertise, Dr. Zinaï will be supporting Tollys in its early clinical developments.
Professor Jean-Yves Blay, current member of the scientific advisory board, takes up chairmanship as company prepares to launch clinical programs.
With more than 35 years experience in the pharmaceutical industry and biotech, Philippe Goupit will lead Tollys’ plans for growth.
Bettina Werle will supervise the laboratory, help set its scientific priorities and lead Tollys’ R&D team.
Support funding for breakthrough innovation will help company’s development in preparation for clinical trials in bladder cancer
Funds will further development of a new cancer immunotherapy: synthetic TLR3 agonist TL-532.
Three senior industry executives join the board of directors.
Triggering & installing efficient anti-tumor immunity
60 avenue Rockefeller
69008 Lyon, FRANCE